Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 03:46 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Study of Trilipix Effects on Lipids and Arteries
NCT01025492 · University of Utah · PHASE4 · terminated · last registry update 2016-09-01 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Collaborator/corporate sponsor withdrew funding and permission to continue.” | – | Registry record, University of Utah |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against PPARA within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2017-08-17Also stopped (terminated): VA Office of Research and Development, fenofibrate + pioglitazone (NCT01289639)
- 2017-06-14Results posted on the registry: University of Miami, Fenofibrate (NCT01965834)
- 2017-06-14Also stopped (terminated): University of Miami, Fenofibrate (NCT01965834)
- 2017-06-02Results posted on the registry: The Scripps Research Institute, Sugar Pill + TRICOR (fenofibrate) (NCT02158273)
- 2017-04-20Results posted on the registry: Centre for Addiction and Mental Health, Gemfibrozil + Placebo (NCT01876810)
- 2017-03-15Results posted on the registry: Sanofi, Alirocumab + Placebo (for Alirocumab) (NCT02023879)
- 2017-03-07Phase 3 first posted: Kowa Research Institute, Inc., K-877 + Placebo (NCT03071692)
- 2017-01-05Phase 3 first posted: Kowa Research Institute, Inc., K-877 + Fenofibrate (NCT03011450)
- 2016-12-23Phase 3 first posted: Kowa Research Institute, Inc., K-877 + Fenofibrate (NCT03001817)
- 2016-10-18Phase 3 first posted: Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Bezafibrate + Ursodeoxycholic Acid (NCT02937012)
- 2016-09-01Also stopped (withdrawn): Essentialis, Inc., 290 mg DCCR + 435 mg DCCR (NCT00973271)
- 2016-07-21Results posted on the registry: VA Office of Research and Development, Fenofibrate 145mg PO QD + Pioglitazone 45 mg PO QD (NCT00470262)
- 2016-07-06Phase 3 first posted: Xijing Hospital of Digestive Diseases, Fenofibrate + UDCA (NCT02823366)
- 2016-07-06Phase 3 first posted: Xijing Hospital of Digestive Diseases, Fenofibrate + UDCA (NCT02823353)
- 2016-05-05Results posted on the registry: Stanford University, Rosiglitazone + Fenofibrate (NCT00186537)
- 2016-03-21Results posted on the registry: Baylor College of Medicine, Niacin + Fenofibrate (NCT00246376)
- 2016-03-10Phase 3 first posted: Genfit, Elafibranor + Placebo (NCT02704403)
- 2016-03-08Phase 3 first posted: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), Bezafibrate + Placebo (NCT02701166)
- 2016-02-19Results posted on the registry: University of Pennsylvania, Fenofibrate (Tricor) tablets + Placebo (NCT01048502)
- 2015-10-22Phase 3 first posted: Sanofi, Alirocumab + Placebo (NCT02584504)
- 2015-09-14Phase 3 first posted: University of Guadalajara, Berberine + Bezafibrate (NCT02548832)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision